Raymond James set a $10.00 target price on IMV (NYSE:IMV) in a research note issued to investors on Thursday morning, BayStreet.CA reports. The firm currently has an outperform rating on the stock.
Several other research firms also recently weighed in on IMV. HC Wainwright set a $11.50 target price on shares of IMV and gave the stock a buy rating in a research note on Monday, September 30th. Wells Fargo & Co assumed coverage on shares of IMV in a research note on Monday, October 28th. They issued a market perform rating for the company. Finally, Zacks Investment Research downgraded shares of IMV from a buy rating to a hold rating in a research note on Saturday, October 26th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $8.94.
Shares of IMV traded down $0.30 during trading hours on Thursday, hitting $2.58. The company’s stock had a trading volume of 8,241 shares, compared to its average volume of 19,864. The business has a 50 day simple moving average of $2.74 and a two-hundred day simple moving average of $3.15. IMV has a 52-week low of $2.25 and a 52-week high of $7.07.
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of Montreal Can increased its stake in shares of IMV by 17.5% in the second quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock worth $260,000 after purchasing an additional 13,228 shares in the last quarter. Hartford Financial Management Inc. grew its stake in IMV by 9.6% during the third quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock valued at $94,000 after acquiring an additional 3,348 shares in the last quarter. Royal Bank of Canada grew its stake in IMV by 3.6% during the second quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock valued at $288,000 after acquiring an additional 3,453 shares in the last quarter. Citadel Advisors LLC purchased a new position in IMV during the second quarter valued at approximately $37,000. Finally, Morgan Stanley grew its stake in IMV by 260.5% during the second quarter. Morgan Stanley now owns 90,368 shares of the company’s stock valued at $264,000 after acquiring an additional 65,300 shares in the last quarter.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
See Also: Why Net Income is Important to Investors
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.